Schizophrenia and Schizoaffective Disorders

Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.

Page 11

Recently published articles about Schizophrenia/Schizoaffective Disorders

PCC
COVID Exacerbates Psychosis in Schizophrenia
Case Report

June 28, 2022

Here, read about a patient with preexisting schizoaffective disorder who experienced an acute worsening of psychosis temporally related to COVID-19.
, ,
JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
, , , et al
JCP
Long-term Outcomes of Early Use of LAIs in Schizophrenia
Original Research

June 1, 2022

Using data from the Taiwan National Health Insurance Research Database, the authors compared long-term effectiveness of switching to long-acting injectable antipsychotics versus remaining on oral antipsychotics.
, ,
JCP
Clozapine Use in Singapore and Hong Kong
Original Research

May 18, 2022

This survey investigated clinicians’ use of clozapine for schizophrenia, beliefs about its effectiveness, and concerns regarding this medication.
, ,
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
, , , et al
JCP
What Is the Role of Digital Medicine for Adherence Monitoring in Patients With SMI?
Commentary

April 11, 2022

This commentary looks at the benefits and limitations of digital medicine systems and discusses a recent trial in schizophrenia patients by Cohen et al.

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe